Live
- YS Jagan Accuses Chandrababu of Conspiring with Delhi leaders to Stop Schemes
- Asthma can negatively affect brain functions: Experts
- IDF takes control of Rafah border crossing in Gaza
- Repurposed cancer drug to help replace insulin therapy for diabetes
- 108 Ambulance Services staff go on statewide protest
- MediaTek unveils new flagship mobile chip in its Dimensity portfolio
- 73 killed in lightning strikes across Myanmar in 2023-24 fiscal year
- Prajwal to likely to arrive in India after today’s elections
- Daksha Nagarkar Opens Up About her Health Condition on Social Media, See Post
- Excise policy row: Manish Sisodia's judicial custody extended till May 15 in CBI case
Dr Reddy's Q4 PAT up 44% at Rs 434 crore
Dr Reddys Laboratories Limited on Friday said its consolidated profit after tax for the quarter-ended March 31, 2019 was up by 44 per cent at Rs 434.4 crore against Rs 302.2 crore in the third quarter of FY 18
Hyderabad: Dr Reddys Laboratories Limited on Friday said its consolidated profit after tax for the quarter-ended March 31, 2019 was up by 44 per cent at Rs 434.4 crore against Rs 302.2 crore in the third quarter of FY 18.
Revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same quarter last fiscal, the city-based drug-maker said.
The CEO and co-chairman of the company G V Prasad said that it has been a good year with a significant turnaround in the financial performance and steady progress on the quality front.
"Looking ahead, we will focus on profitable growth, continue the emphasis on operational excellence and drive innovation to deliver value to patients and healthcare systems worldwide," he said.
For FY19, PAT stood at Rs 1,880 crore while revenue was 15,385 crore.Revenue from global generics segment in the Q4 was reported at Rs 3,038 crore a year-on-year growth of nine per cent over the same quarter last year, primarily driven by contributions from emerging markets and Europe.
Revenue from North America grew by three per cent to Rs 1,496 crore against Rs 1,449 crore in Q4 of FY18.
Revenue from pharmaceutical services and active ingredients was at Rs 676.50 crore in the fourth quarter with eight per cent growth over the Q4 of FY 18.
